REGULAR CONTENT
Final ID
470
Type
Original Scientific Research-Oral or Pos
Authors
S Cole1, P Park1, R Bittman1, J Newsome1, Z Bercu1, R Williams2, J Prologo1
Institutions
1Emory University School of Medicine, Atlanta, GA, 2Quantum Radiology, Marietta, GA
Purpose
Desmoid fibromatosis tumors are benign, locally aggressive tumors that tend to recur even after standard management with surgery, radiation, and chemotherapy. The objective of this study is to evaluate the safety and efficacy of CT-guided percutaneous cryoablation for the treatment of inoperable, locally aggressive extraabdominal desmoid (EAD) tumors.
Materials & Methods
A retrospective search identified 11 patients (mean age 41, range 21-71) who underwent percutaneous cryoablation for the treatment of inoperable, locally aggressive EAD tumors during the period of January 2010 to June 2016. A total of 13 tumors were treated in these 11 patients. Pre- and post-procedure imaging was analyzed to assess changes in tumor volume. Charts were reviewed to evaluate technical and clinical success.
Results
The mean number of cryoablation procedures per patient was 3.4 (range 1-7). All 37 procedures were technically successful. All 11 patients reported symptomatic relief following therapy. Mean time from pre-treatment imaging to latest follow-up imaging was 2.5 years (range 7 months – 6 years 3 months). Over this time period, the mean change in approximate tumor volume was + 3% (range -94 to +127%). Seven of the thirteen tumors demonstrated growth arrest. Of the six tumors to demonstrate volume increase, three underwent further cryoablation, one is scheduled for further cryoablation, and two are undergoing active surveillance. No major complications were observed. One patient developed post-procedural foot drop which improved over time, as well as one mild case of skin freeze at the ablation site.
Conclusions
CT-guided percutaneous cryoablation is a safe and effective option for the treatment of locally aggressive EAD tumors. Further studies are necessary to determine long-term clinical success and identify predictors of success.
Final ID
470
Type
Original Scientific Research-Oral or Pos
Authors
S Cole1, P Park1, R Bittman1, J Newsome1, Z Bercu1, R Williams2, J Prologo1
Institutions
1Emory University School of Medicine, Atlanta, GA, 2Quantum Radiology, Marietta, GA
Purpose
Desmoid fibromatosis tumors are benign, locally aggressive tumors that tend to recur even after standard management with surgery, radiation, and chemotherapy. The objective of this study is to evaluate the safety and efficacy of CT-guided percutaneous cryoablation for the treatment of inoperable, locally aggressive extraabdominal desmoid (EAD) tumors.
Materials & Methods
A retrospective search identified 11 patients (mean age 41, range 21-71) who underwent percutaneous cryoablation for the treatment of inoperable, locally aggressive EAD tumors during the period of January 2010 to June 2016. A total of 13 tumors were treated in these 11 patients. Pre- and post-procedure imaging was analyzed to assess changes in tumor volume. Charts were reviewed to evaluate technical and clinical success.
Results
The mean number of cryoablation procedures per patient was 3.4 (range 1-7). All 37 procedures were technically successful. All 11 patients reported symptomatic relief following therapy. Mean time from pre-treatment imaging to latest follow-up imaging was 2.5 years (range 7 months – 6 years 3 months). Over this time period, the mean change in approximate tumor volume was + 3% (range -94 to +127%). Seven of the thirteen tumors demonstrated growth arrest. Of the six tumors to demonstrate volume increase, three underwent further cryoablation, one is scheduled for further cryoablation, and two are undergoing active surveillance. No major complications were observed. One patient developed post-procedural foot drop which improved over time, as well as one mild case of skin freeze at the ablation site.
Conclusions
CT-guided percutaneous cryoablation is a safe and effective option for the treatment of locally aggressive EAD tumors. Further studies are necessary to determine long-term clinical success and identify predictors of success.